NCT04618380

Brief Summary

Primary objective of this study was to compare the efficacy of premium monovision with Restor and Panoptix, against other prevalent monovision techniques and against bilateral Panoptix implantation in a sample of patients following lens-extraction surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 5, 2020

Completed
Last Updated

November 9, 2020

Status Verified

November 1, 2020

Enrollment Period

2.6 years

First QC Date

November 1, 2020

Last Update Submit

November 5, 2020

Conditions

Keywords

pseudophakic presbyopic correctionpremium monovisionmyopic monovisionmultifocal intraocular lenseshybrid monovision

Outcome Measures

Primary Outcomes (5)

  • Binocular uncorrected distant visual acuity [bUD-VA]

    bUD-VA is obtained using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance. This parameter is obtained six months following the operation of the second eye.

    through study completion, an average of 2.5years

  • Binocular uncorrected intermediate reading acuity (at 60cm) [bUI-RA)]

    bUI-RA is obtained using the DDART reading test, which is based on the Greek version of MNREAD. This parameter is obtained six months following the operation of the second eye.

    through study completion, an average of 2.5years

  • binocular uncorrected near reading acuity (at 40cm) [bUN-RA]

    bUN-RA is obtained using the DDART reading test, which is based on the Greek version of MNREAD. This parameter is obtained six months following the operation of the second eye.

    through study completion, an average of 2.5years

  • binocular uncorrected intermediate critical print size (at 60cm) [bUI-CPS]

    bUI-CPS is obtained using the DDART reading test, which is based on the Greek version of MNREAD. This parameter is obtained six months following the operation of the second eye.

    through study completion, an average of 2.5years

  • binocular uncorrected near critical print size (at 40cm )[bUN-CPS]

    bUN-CPS is obtained using the DDART reading test, which is based on the Greek version of MNREAD. This parameter is obtained six months following the operation of the second eye.

    through study completion, an average of 2.5years

Secondary Outcomes (4)

  • Dysphotopsia symptoms

    through study completion, an average of 2.5years

  • Contrast sensitivity

    through study completion, an average of 2.5years

  • Spectacle independence

    through study completion, an average of 2.5years

  • Subjective satisfaction using Visual Function Index (VF-14 instrument) (total score, VF14-NV score & VF14-DV score)

    through study completion, an average of 2.5years

Study Arms (4)

Bilateral trifocal implantation

Bilateral implantation of trifocal diffractive intraocular lenses (Panoptix, Alcon) targeting emmetropia

Diagnostic Test: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity

Myopic monovision

The dominant eye defocus is targeted to -0.50 diopters while the recessive one to -1.25 diopters with bilateral implantation of monofocal intraocular lenses (SN60WF, Alcon)

Diagnostic Test: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity

Hybrid monovision

Hybrid monovision combines a monofocal intraocular (SN60WF, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one

Diagnostic Test: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity

Premium monovision

Participants received a bifocal hybrid (refractive at the centre, diffractive at the periphery) intraocular lens (Restor +2.50 diopters, Alcon) in the dominant eye and a trifocal diffractive intraocular lens (Panoptix, Alcon) in the recessive one, targeting emmetropia in both eyes.

Diagnostic Test: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity

Interventions

The following clinical indexes are evaluated: 1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance 2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and 3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS). All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD. Contrast sensitivity are evaluated with the Pelli-Robson test.

Bilateral trifocal implantationHybrid monovisionMyopic monovisionPremium monovision

Eligibility Criteria

Age45 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants were recruited from the Cataract Service of the University Hospital of Alexandroupolis in a consecutive-if-eligible basis.

You may qualify if:

  • Diagnosis of senile cataract with stage 2 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale

You may not qualify if:

  • Manifest astigmatism \> 1.00 diopters
  • Reports of headaches and/or eyestrain associated with visual activities
  • Positive, pathologic ocular cover test (near \& distant) and / or the Mallett's disparity test (near \& distant) and the double Maddox rod test
  • Endothelial cell count less than 1900/mm2
  • Glaucoma
  • intraocular pressure-lowering medications
  • Former incisional surgery
  • Former diagnosis of corneal disease
  • Former diagnosis of fundus disease
  • Diabetes
  • Autoimmune diseases
  • Mental diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology, University Hospital of Alexandroupolis

Alexandroupoli, Evros, 68100, Greece

Location

Related Publications (2)

  • Labiris G, Panagiotopoulou EK, Chatzimichael E, Tzinava M, Mataftsi A, Delibasis K. Introduction of a digital near-vision reading test for normal and low vision adults: development and validation. Eye Vis (Lond). 2020 Oct 22;7:51. doi: 10.1186/s40662-020-00216-0. eCollection 2020.

  • Labiris G, Panagiotopoulou EK, Perente A, Ntonti P, Delibasis K, Fotiadis I, Konstantinidis A, Dardabounis D. Premium Monovision versus Bilateral Myopic Monovision, Hybrid Monovision and Bilateral Trifocal Implantation: A Comparative Study. Clin Ophthalmol. 2022 Mar 4;16:619-629. doi: 10.2147/OPTH.S351091. eCollection 2022.

MeSH Terms

Conditions

PresbyopiaRefractive ErrorsCataract

Interventions

Contrast Sensitivity

Condition Hierarchy (Ancestors)

Eye DiseasesLens Diseases

Intervention Hierarchy (Ancestors)

Visual AcuityVision TestsDiagnostic Techniques, OphthalmologicalDiagnostic Techniques and ProceduresDiagnosisOcular Physiological Phenomena

Study Officials

  • Georgios Labiris, MD,PHD

    Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor (Associate) of Democritus University of Thrace

Study Record Dates

First Submitted

November 1, 2020

First Posted

November 5, 2020

Study Start

January 1, 2018

Primary Completion

July 31, 2020

Study Completion

November 1, 2020

Last Updated

November 9, 2020

Record last verified: 2020-11

Locations